ReNeuron Group (LON:RENE) issued its quarterly earnings data on Thursday. The company reported GBX (45.20) (($0.59)) earnings per share for the quarter, topping the consensus estimate of GBX (49.80) (($0.65)) by GBX 4.60 ($0.06), Bloomberg Earnings reports.
Shares of ReNeuron Group stock opened at GBX 237.50 ($3.10) on Friday. ReNeuron Group has a twelve month low of GBX 29.50 ($0.39) and a twelve month high of GBX 342 ($4.47). The business has a 50-day simple moving average of GBX 250.07. The firm has a market cap of $75.53 million and a PE ratio of -5.61.
In other news, insider Christopher Evans bought 10,000 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was bought at an average cost of GBX 229 ($2.99) per share, for a total transaction of £22,900 ($29,922.91).
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Featured Article: Stock Portfolio Tracker
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.